论文部分内容阅读
目的观察艾塞那肽联合二甲双胍治疗对口服降糖药(OAD)控制不佳的2型糖尿病(T2DM)患者的临床疗效。方法 31例既往使用OAD控制不佳的T2DM患者,改用艾塞那肽联合二甲双胍治疗3个月,观察治疗前后空腹血糖(FPG)、餐后2h血糖(2hPG)、糖化血红蛋白(HbA1c)、体重、体质指数(BMI)、C-肽(空腹及餐后2h)、总胆固醇(TC)、甘油三酯(TG)、高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C)的变化。结果治疗后FPG、2hPG、HbA1c、体重、BMI、TC、TG、LDL-C均有明显下降(P均<0.01)。C-肽(空腹及餐后2h)未发现明显变化(P>0.05)。低血糖发生率为3.23%。结论艾塞那肽联合二甲双胍能有效地控制T2DM患者的血糖,减轻体重,且发生低血糖的风险低。
Objective To observe the clinical efficacy of exenatide and metformin in the treatment of type 2 diabetes mellitus (T2DM) patients with poorly controlled oral hypoglycemic agents (OAD). Methods 31 cases of T2DM patients with poorly controlled OAD were enrolled and treated with exenatide and metformin for 3 months. The levels of fasting blood glucose (FPG), postprandial 2h blood glucose (2hPG), HbA1c, body weight BMI, C-peptide (fasting and postprandial 2h), TC, TG, HDL-C, C) changes. Results After treatment, the levels of FPG, 2hPG, HbA1c, body weight, BMI, TC, TG and LDL-C were significantly decreased (all P <0.01). C-peptide (fasting and postprandial 2h) found no significant change (P> 0.05). The incidence of hypoglycemia was 3.23%. Conclusion Exenatide combined with metformin can effectively control the blood sugar of T2DM patients, reduce body weight, and low risk of hypoglycemia.